Skip to main content
Clinical Trials/JPRN-jRCT2032200033
JPRN-jRCT2032200033
Completed
Phase 3

A Multicenter, Prospective, Randomized Controlled Trial: SMC-01: A Mobile Medical Application to Improve Self-Management of Patients with Type 2 Diabetes

Ohnishi Yukiko0 sites200 target enrollmentMay 17, 2020

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
Ohnishi Yukiko
Enrollment
200
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 17, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ohnishi Yukiko

Eligibility Criteria

Inclusion Criteria

  • 1\) Outpatients who are 20 years of age or older at the time of obtaining consent (regardless of gender)
  • 2\) Patients who have written consent at the time of Visit 1
  • 3\) Patients who, at Visit 1, have been diagnosed with type 2 diabetes for at least 12 weeks (84 days)
  • 4\) Patients being treated with diet and exercise therapy alone or taking hypoglycemic medications in addition to diet and exercise therapy, who have been on the same therapy for at least 12 weeks (84 days) at the time of Visit 1\.
  • 5\) Patients with a Visit 1 HbA1c value of 7\.0% to 9\.0% or less
  • 6\) Patients who have a smartphone device and have been using it continuously for at least 12 weeks (84 days) at the time of Visit 1\.
  • 7\) Patients who have been confirmed by the investigator as having no problems with the input eligibility of the test device.

Exclusion Criteria

  • 1\) Women who wish to become pregnant, are pregnant, or are breastfeeding.
  • 2\) Premenopausal women with a positive pregnancy test (urine)
  • 3\) Patients who have been diagnosed with type 1 diabetes
  • 4\) Patients who have been diagnosed with secondary diabetes mellitus
  • 5\) Patients who received insulin within 12 weeks (84 days) retroactive to Visit 1
  • 6\) Patients with a history of requiring third party intervention for the treatment of hypoglycemia
  • 7\) Patients with or undergoing treatment for diabetic proliferative retinopathy
  • 8\) Patients who developed cardiovascular disease within 12 weeks (84 days) retroactive to Visit 1
  • 9\) Patients with noncompensated heart failure
  • 10\) Patients with serious hepatic impairment (ALT value (central bulk measurement at Visit 1\) greater than 3 times the upper limit of the reference value)

Outcomes

Primary Outcomes

Not specified

Similar Trials